Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Rheumatoid Arthritis Clinical Trial

Official title:

A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00848354
• Other study ID #: 0881A1-4532
• Secondary ID: B1801004
• Status: Completed
• Phase: Phase 4
• First received: February 18, 2009
• Last updated: December 11, 2015
• Start date: June 2009
• Est. completion date: April 2013

Study information

• Verified date: December 2015
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
• Study type: Interventional

Clinical Trial Summary

The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe rheumatoid arthritis over 128 weeks. Phase 1 is a randomized 24 week treatment period; Phase 2 is an optional open-label 104 week period that allows the investigator to choose continuation with the phase I treatment or the addition, discontinuation or titration of other DMARD therapy already being utilized for the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 429
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Rheumatoid Arthritis (RA)

• Currently receiving a suboptimal response to a stable dose of methotrexate for treatment of Rheumatoid Arthritis (RA)

• Active Rheumatoid Arthritis (RA) at time of screening and baseline

Exclusion Criteria:

• Previous or current treatment with etanercept, other tumor necrosis factor-alpha inhibitors, or other biologic agents

• Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, at screening

• Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, within 3 months before screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Biological:
• Phase 1: Etanercept
Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24

Drug:
• Phase 1: Methotrexate
Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
• Phase 2: Optional ETN, SSZ, HCQ, MTX
Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128. Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128. Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128. Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.
• Phase 1: Methotrexate
Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
• Phase 1: Conventiaonal DMARD
Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.

Locations

Country	Name	City	State
Argentina	Atencion Integral en Reumatologia	Buenos Aires
Argentina	Centro de Investigaciones en Enfermedades Reumaticas	Buenos Aires
Argentina	Hospital Britanico	Buenos Aires
Argentina	OMI	Buenos Aires
Argentina	Consultorios Especializados en Investigaciones Medicas	Capital Federal	Buenos Aires
Argentina	Centro de Osteopatías Médicas	Ciudad Autónoma de Buenos Aires
Argentina	Investigaciones Reumatológicas y Osteológicas	Ciudad Autónoma de Buenos Aires
Argentina	Sanatorio Mayo	Cordoba
Argentina	Hospital Escuela Gral. San Martin	Corrientes
Argentina	Instituto CAICI	Rosario	Santa Fe
Argentina	CER San Juan	San Juan	Provinica de San Juan
Argentina	Centro Medico Privado de Reumatologia	San Miguel de Tucuman
Argentina	Centro de Investigaciones Reumatologicas	Tucuman
Chile	Dr Miranda Private Practice	Santiago	Region Metropolitana
Chile	Hospital del Salvador	Santiago	Region Metropolitana
Colombia	Centro de Reumatologia y Ortopedia	Barranquilla	Atlantico
Colombia	IPS Centro Integral de Rematología del Caribe S.A.S CIRCARIBE S.A.S Sede 1	Barranquilla	Atlantico
Colombia	IPS Centro Integral de Rematología del Caribe S.A.S CIRCARIBE S.A.S Sede 2	Barranquilla	Atlantico
Colombia	Centro Integral de Reumatologia e Inmunologia LTDA	Bogota	Cundinamarca
Colombia	Foqus Ips Ltda	Bogota	Cundinamarca
Colombia	Fundacion Instituto de Reumatologia Fernando Chalem	Bogota	Cundinamarca
Colombia	Riesgo de fractura S.A. Clinica de Artritis y Rehabilitacion	Bogota	Cundinamarca
Colombia	Centro Medico Carlos Ardila Lulle	Bucaramanga	Santander
Colombia	Servimed EU	Bucaramanga	Santander
Colombia	Preventive Care Ltda	Chia	Cundinamarca
Colombia	Reumalab	Medellin	Antioquia
Mexico	Centro de Investigación y Biomedicina de Chihuahua	Chihuahua
Mexico	Hospital Christus Mugerza	Chihuahua
Mexico	Hospital Christus Muguerza del Parque	Chihuahua
Mexico	Hospital Angeles Chapalita	Guadajara	Jalisco
Mexico	Centro de Especialidades Medicas del Sureste SA de CV	Merida	Yucatan
Panama	Centro de Infusion Marbella	Panama
Panama	Centro de Investigacion Marbella	Panama

Sponsors (2)

Lead Sponsor	Collaborator
Pfizer	Amgen

Countries where clinical trial is conducted

Argentina,  Chile,  Colombia,  Mexico,  Panama, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response at Week 24	ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of the Health Assessment Questionnaire; HAQ); and C-Reactive Protein (CRP).	Week 24	No
Secondary	Change From Baseline in HAQ Score at Week 24	HAQ: self-reported, valid assessment of functional disability in rheumatoid arthritis. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ score range: 0-3: without any difficulty: 0, with some difficulty: 1, with much difficulty: 2, unable to do: 3. HAQ total scores expressed as overall mean score with range 0-3: 0-0.25: normal functioning; 0.25-0.5: mild functional limitation; 0.5-1: moderate functional limitation; more than 1: significant functional limitation.	Baseline and Week 24	No
Secondary	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Baseline and Week 24	No
Secondary	Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdH mTSS), Annualized, at Week 24	mTSS: sum of erosion and joint space narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.	Baseline and Week 24	No
Secondary	Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28 calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour; mm/hour) and the participant`s general health using a 100 mm-visual analog scale (VAS). DAS28<3.2 indicates low disease activity and DAS28<2.6 remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28 calculated from the number of swollen joints and painful joints using the 28 joints count, the ESR (mm/hour) and the participant`s general health using a 100 mm-VAS. DAS28<3.2 indicates low disease activity and DAS28<2.6 remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Summary of Changes in Therapy at the Beginning of Phase 2	The investigators were allowed to alter each participant`s therapy at the beginning of Phase 2. Continuations, discontinuations and additions made to Phase 1 treatment regimen were summarized.	Week 24	No
Secondary	Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20	ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.	Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20	No
Secondary	Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	ACR50 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 50 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	ACR20 response: greater than or equal to 20 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 20 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	ACR20 response: greater than or equal to 20 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 20 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	ACR70 response: greater than or equal to 50 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 70 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and CRP.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	ACR70 response: greater than or equal to 70 percent improvement from Baseline in tender joint count and swollen joint count; and greater than or equal to 70 percent improvement from Baseline in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; participant's self-assessed disability (disability index of HAQ); and ESR.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS calculated from number of painful joints using the ritchie articular index (RAI), number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS=2.4 indicates low disease activity and DAS<1.6 remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS=2.4 indicates low disease activity and DAS<1.6 remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS<2.4 (Low Disease Activity) Response at Week 24	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 24	No
Secondary	Percentage of Participants Achieving DAS<1.6 (Remission) Response at Week 24	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 24	No
Secondary	Percentage of Participants Achieving DAS Improvement of =0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS Improvement of =0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS Improvement of =1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS Improvement of =1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS calculated from number of painful joints using RAI, number of swollen joints using the same 44 joints as in RAI, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS<2.4: low disease activity, DAS<1.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS-based EULAR response was defined as: DAS-value =3.7 and DAS-improvement from Baseline >0.6; DAS-value >3.7 and DAS-improvement from Baseline >1.2	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS-based EULAR response was defined as: DAS-value =3.7 and DAS-improvement from Baseline >0.6; DAS-value >3.7 and DAS-improvement from Baseline >1.2	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS-based EULAR response was defined as: DAS-value =2.4 and DAS-improvement from Baseline >1.2.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS-based EULAR response was defined as: DAS-value =2.4 and DAS-improvement from Baseline >1.2.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS28-based EULAR response was defined as: DAS28-value =5.1 and DAS28-improvement from Baseline >0.6; DAS28-value >5.1 and DAS28-improvement from Baseline >1.2	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Moderate or good DAS28-based EULAR response was defined as: DAS28-value =5.1 and DAS28-improvement from Baseline >0.6; DAS28-value >5.1 and DAS28-improvement from Baseline >1.2	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS28-based EULAR response was defined as: DAS28-value =3.2 and DAS28-improvement from Baseline >1.2.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from Baseline and the level of disease activity reached. Good DAS28-based EULAR response was defined as: DAS28-value =3.2 and DAS28-improvement from Baseline >1.2.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS28 Improvement of =0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS28 Improvement of =0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Percentage of Participants Achieving DAS28 Improvement of =1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Percentage of Participants Achieving DAS28 Improvement of =1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, ESR (mm/hour) and participant`s general health using a 100 mm-VAS. DAS28<3.2: low disease activity, DAS28<2.6: remission.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	Painful joint count is a physical assessment of the ACR-specified 68 joint set for tenderness/pain. Each joint is rated as either painful or not painful with the total number of painful joints reported as the score. Score range is from 0-68 with lower scores indicating the better outcome.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	Painful joint count is a physical assessment of the ACR-specified 68 joint set for tenderness/pain. Each joint is rated as either painful or not painful with the total number of painful joints reported as the score. Score range is from 0-68 with lower scores indicating the better outcome.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	Swollen joint count is a physical assessment of the ACR-specified 66 joint set for swelling. Each joint is rated as either swollen or not swollen with the total number of swollen joints reported as the score. Score range is from 0-66 with lower scores indicating the better outcome.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	Swollen joint count is a physical assessment of the ACR-specified 66 joint set for swelling. Each joint is rated as either swollen or not swollen with the total number of swollen joints reported as the score. Score range is from 0-66 with lower scores indicating the better outcome.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The participant`s global disease activity was estimated over the preceding 2-3 days on a scale from 0 (no disease activity) to 10 (extreme disease activity) by the physician.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The participant`s global disease activity was estimated over the preceding 2-3 days on a scale from 0 (no disease activity) to 10 (extreme disease activity) by the physician.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24	The participant assessed overall arthritis activity on a scale from 0 (no disease activity) to 10 (extreme disease activity).	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The participant assessed overall arthritis activity on a scale from 0 (no disease activity) to 10 (extreme disease activity).	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The duration of morning stiffness was determined over the preceding 2 days using a 2-question worksheet.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The duration of morning stiffness was determined over the preceding 2 days using a 2-question worksheet.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The participants had to indicate on a 100 mm-VAS (0 mm: very well, 100 mm: extremely bad) in general how they rated their health over the preceding 2-3 weeks.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The participants had to indicate on a 100 mm-VAS (0 mm: very well, 100 mm: extremely bad) in general how they rated their health over the preceding 2-3 weeks.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The participants had to indicate on a 100 mm-VAS (0 mm: no pain, 100 mm: pain as bad as it could be) the amount of pain they experienced over the preceding 2-3 days.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The participants had to indicate on a 100 mm-VAS (0 mm: no pain, 100 mm: pain as bad as it could be) the amount of pain they experienced over the preceding 2-3 days.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The participants had to indicate on a 100 mm-VAS (0 mm: no fatigue, 100 mm: a great deal of fatigue) how much of a problem had fatigue or tiredness been for them in the preceding week.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	The participants had to indicate on a 100 mm-VAS (0 mm: no fatigue, 100 mm: a great deal of fatigue) how much of a problem had fatigue or tiredness been for them in the preceding week.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in Joint Space Narrowing Score Using vdH mTSS at Week 24	mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.	Week 24	No
Secondary	Change From Baseline in Erosion Score Using vdH mTSS at Week 24	mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Each x-ray visit included 4 films, each of which were read by 2 readers. The mTSS was calculated by the images scored for erosions and JSN. An increase in mTSS from Baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.	Week 24	No
Secondary	Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hour. A higher rate is consistent with inflammation. ESR was performed at the investigative site using an ESR kit supplied by the centralized laboratory.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hour. A higher rate is consistent with inflammation. ESR was performed at the investigative site using an ESR kit supplied by the centralized laboratory.	Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128	No
Secondary	Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. CRP was analysed at a central laboratory.	Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 50, Week 76, Week 102, and Week 128	No
Secondary	Change From Baseline in SF-36 Health Survey Mental Component Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 50, Week 76, Week 102, and Week 128	No
Secondary	Change From Baseline in SF-36 Health Survey Physical Component Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 50, Week 76, Week 102, and Week 128	No
Secondary	Change From Baseline in SF-36 Health Survey Bodily Pain Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Role Limitations Due to Emotional Problems Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey General Health Perceptions Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Mental Health Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Physical Functioning Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Role Limitations Due to Physical Health Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No
Secondary	Change From Baseline in SF-36 Health Survey Social Functioning Domain Score at Week 8, Week 16, and Week 24	The SF-36 is standardized 36-item survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health perception, vitality, and mental health. Domain scores range from 0-100, with greater scores reflecting better health status. Two additional overall summary scores - physical and mental component scores - were also obtained. Summary scores are standardized where the general population mean is 50 with a standard deviation of 10. Greater scores again indicate better health status.	Week 8, Week 16, and Week 24	No

External Links

•   To obtain contact information for a study center near you, click here.